drugset / Trial / NCT02920450
Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this research study is to determine if the study drug, Gedatolisib (PF-05212384), given in combination with paclitaxel and carboplatin will work against unresectable non-small cell lung cancer.
Timeline
- Start
- 2017-09-25
- Primary completion
- 2019-01-02
- Completion
- 2019-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gedatolisib | Small molecule | 110 mg | Intravenous |
| Subject | Gedatolisib | Small molecule | 150 mg | Intravenous |
| Subject | Gedatolisib | Small molecule | 180 mg | Intravenous |
| Background | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 200 mg/m2 | — |